Libtayo (cemiplimab) and Keytruda (pembrolizumab) have demonstrated to be a beneficial treatment option for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). Could adding Opdivo (nivolumab) as a treatment be successful? Continue HERE to find out more
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
(Visited 3 times, 1 visits today)
Last modified: February 7, 2025
